KR970705403A - 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant) - Google Patents
비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant)Info
- Publication number
- KR970705403A KR970705403A KR1019970701224A KR19970701224A KR970705403A KR 970705403 A KR970705403 A KR 970705403A KR 1019970701224 A KR1019970701224 A KR 1019970701224A KR 19970701224 A KR19970701224 A KR 19970701224A KR 970705403 A KR970705403 A KR 970705403A
- Authority
- KR
- South Korea
- Prior art keywords
- vaccine
- composition
- antigen
- enterotoxin
- coli heat
- Prior art date
Links
- 239000000147 enterotoxin Substances 0.000 title claims abstract 13
- 231100000655 enterotoxin Toxicity 0.000 title claims abstract 13
- 101710146739 Enterotoxin Proteins 0.000 title claims abstract 12
- 239000002671 adjuvant Substances 0.000 title claims 4
- 231100000252 nontoxic Toxicity 0.000 title 2
- 230000003000 nontoxic effect Effects 0.000 title 2
- 241000588724 Escherichia coli Species 0.000 claims abstract 11
- 239000000427 antigen Substances 0.000 claims abstract 9
- 102000036639 antigens Human genes 0.000 claims abstract 9
- 108091007433 antigens Proteins 0.000 claims abstract 9
- 230000028993 immune response Effects 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 5
- 102000004142 Trypsin Human genes 0.000 claims 4
- 108090000631 Trypsin Proteins 0.000 claims 4
- 230000001681 protective effect Effects 0.000 claims 4
- 239000012588 trypsin Substances 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000000568 immunological adjuvant Substances 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 231100000331 toxic Toxicity 0.000 claims 3
- 230000002588 toxic effect Effects 0.000 claims 3
- 108010055044 Tetanus Toxin Proteins 0.000 claims 2
- 230000000240 adjuvant effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229930186900 holotoxin Natural products 0.000 claims 2
- 229940041323 measles vaccine Drugs 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 229940118376 tetanus toxin Drugs 0.000 claims 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000589876 Campylobacter Species 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 229940033330 HIV vaccine Drugs 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 229940124859 Rotavirus vaccine Drugs 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 241000607598 Vibrio Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 229960005004 cholera vaccine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000688 enterotoxigenic effect Effects 0.000 claims 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960003971 influenza vaccine Drugs 0.000 claims 1
- 229940124735 malaria vaccine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000000010 microbial pathogen Species 0.000 claims 1
- 229940095293 mumps vaccine Drugs 0.000 claims 1
- 229960002566 papillomavirus vaccine Drugs 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229940124856 vaccine component Drugs 0.000 claims 1
- 229940021648 varicella vaccine Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 229940126578 oral vaccine Drugs 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
- Dental Preparations (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
독성은 상실하였으나 이의 면역학적 활성은 보유하고 있는 대장균 열-불안정한 장독소의 신규한 돌연변이 형으로된 조성물과 이의 용도를 제공한다. 이와 같은 장독소는 경구 백신 준비물의 일부로써 투여하였을 때 항원에 대한 증가된 면역반응을 얻기 위해 무관한 항원과 복합하여 사용될 수도 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (22)
- 면역학적 어쥬번트 활성을 가지면서 NAD-아그마틴-ADP-리보실 전달효소 검사에 의해 측정하였을 때 ADP-리보실화 효소활성이 부족한 대장균 열-불안정한 장독소 할로톡신의 돌연변이 형으로 구성된 것을 특징으로 하는 조성물.
- 할로톡신의 A 소단위가 트립신에 의해 절단되진 않은 면역학적 어쥬벤트 활성이 있는 대장균 열 불안정한 장독소 할로톡신의 돌연변이 형으로 구성된 것을 특징으로 하는 조성물.
- 제1항 또는 제2항에 있어서, 조성물은 대장균 열-불안정한 장독소의 A 소단위와 B 소단위 모드를 발현하고 ATCC에 기탁되어 기탁번호가 696883인 대장균 LTR192G에 포함된 플라스미드 pBD95에 의해 인코드되는 것을 특징으로 하는 조성물.
- 제1항 내지 2항에 따른 조성물과 복합된 항원으로 구성된 것을 특징으로 하는 백신 조성물.
- 제4항에 있어서, 항원은 인플루엔자 백신, 바리셀라 백신, 디프테리아 독소, 테타누스 독소, 페로트시스 백신 일본 엔세팔리티스 백신, 페르투시스, 디프테이아와 테타느스독소의 혼합형 백신, 라임 질병백신, 폴리오백신, 말라리아 백신, 허피스 백신, HIV 백신, 파필로마 바이러스 백신, 헤파타이티스 B백신, 로타 백신, 캄필로박터 백신,콜레라 백신,장병원성 대장균 백신, 장독소 대장균 백신, 쉬스토소마이시스 백신, 홍역 백신, 루베라 백신, 멈프스 백신, 홍역, 루벨라와 멈프스 혼합형 백신 그리고 미코플라스마 백신에서 선택되는 것을 특징으로 하는 백신 조성물.
- 숙주에서 병원균에 보호성 면역반응을 만드는데 유용한 조성물에 있어서, 제1항 또는 2항에 따른 조성물의 어쥬번트 효과량과 항원 효과량의 혼합물로 구성된 것을 특징으로 하는 조성물.
- 병원균에 대한 숙주에서 보호성 면역 반응을 만드는데 유용한 키트에 있어서, 두가지 성분으로 구성되는 데 a) 효과량의 항원과 b) NAD-아크마틴 ADP-리보실전달 효소 검사에 의해 측정하였을 때 ADP-리보실화 효소 활성이 부족하나 면역학적 어쥬번트 활성을 가지는 대장균 열-불안정한 장독소 홀로톡신 돌연변이체의 어쥬번트 효과량으로 구성되고 이때, 이 두성분을 경구을 투여가능한 담체에 있고 서로 혼합시킨후 함께 투여하거나 또는 짧은 시간 간격내에서 별도로 투여될 수 있는 것을 특징으로 하는 키트.
- 제1항 또는 6항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 조성물.
- 제4항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 키트.
- 제7항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 키트.
- 제1항 또는 6항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
- 제4항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
- 제7항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
- 병원균에 대한 숙주에서 보호성 면역 반응을 만드는데 방법에 있어서, 효과량의 항원과 NAD-아크마틴 ADP-리보실전달 효소 검사에 의해 측정하였을 때 ADP-리보실화 효소 활성이 부족하나 면역학적 어쥬번트 활성을 가지는 대장균 열-불안정한 장독소 홀로톡신 돌연변이체의 어쥬번트 효과량을 경구을 투여가능한 담체에 있고 서로 혼합시킨후 함께 투여하는 것을 특징으로 하는 방법.
- 제14항에 있어서, 혈청반응이 생산되는 것을 특징으로 한는 방법.
- 제14항에 있어서, 점막반응이 생산되는 것을 특징으로 한는 방법.
- 제14항에 있어서, 항원이 연속 촉진주사가 제공되는 것을 특징으로 하는 방법.
- 제14항에 있어서, 항원이 박테리아, 바이러스, 프로토조아, 곰팡이, 기생충, 그리고 다른 미생물 병원균에서 유도되는 것을 특징으로 하는 방법.
- 제14항에 있어서, 혼합물은 단일 약량으로 수송되는 것을 특징으로 하는 방법.
- 장독소 발테리아 유기체에 대한 보호성 면역 반응을 유도하는 방법에 있어서, 장독소 박테리아 유기체에 대한 백신성분으로써 mLT를 이용하는 것으로 구성된 것을 특징으로 하는 방법.
- 제20항에 있어서, 장독성 박테리아 유기체는 콜레라-형 독소를 발현하는 장독성 박테리아 유기체에서 선택되는 것을 특징으로 하는 방법.
- 제20항에 있어서, 장독성 박테리아 유기체는 대장균spp와 비브리오 spp에서 선택되는 것을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/296,848 US6019982A (en) | 1994-08-26 | 1994-08-26 | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| US296,848 | 1994-08-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970705403A true KR970705403A (ko) | 1997-10-09 |
| KR100399258B1 KR100399258B1 (ko) | 2003-12-31 |
Family
ID=23143827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970701224A KR100399258B1 (ko) | 1994-08-26 | 1995-07-18 | 비독성경구용어쥬번트로써효과적인장독소돌연변이체 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6019982A (ko) |
| EP (1) | EP0777490B1 (ko) |
| JP (1) | JP3860208B2 (ko) |
| KR (1) | KR100399258B1 (ko) |
| CN (1) | CN1182868C (ko) |
| AT (1) | ATE326231T1 (ko) |
| AU (1) | AU709779B2 (ko) |
| BR (1) | BR9508633A (ko) |
| CA (1) | CA2198586C (ko) |
| CZ (1) | CZ298131B6 (ko) |
| DE (1) | DE69534992T2 (ko) |
| DK (1) | DK0777490T3 (ko) |
| ES (1) | ES2265148T3 (ko) |
| FI (1) | FI120137B (ko) |
| HU (1) | HU222985B1 (ko) |
| NO (1) | NO317942B1 (ko) |
| NZ (1) | NZ291262A (ko) |
| PL (1) | PL182667B1 (ko) |
| PT (1) | PT777490E (ko) |
| RU (1) | RU2160606C2 (ko) |
| WO (1) | WO1996006627A1 (ko) |
| ZA (1) | ZA956412B (ko) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| AU3630093A (en) * | 1992-03-02 | 1993-10-05 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
| ATE275970T1 (de) | 1993-10-05 | 2004-10-15 | Celltech Pharmaceuticals Ltd | Impfstoffzusammensetzungen |
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| ATE229978T1 (de) * | 1994-07-01 | 2003-01-15 | Chiron Corp | Helicobacter proteine und impstoffe |
| US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| FR2726472B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin |
| GB9626864D0 (en) * | 1996-12-24 | 1997-02-12 | Smithkline Beecham Biolog | Vaccine |
| ES2283012T3 (es) * | 1996-01-04 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Bacterioferritina de helicobacter pylori. |
| GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US6036953A (en) * | 1996-11-29 | 2000-03-14 | The General Hospital Corporation | Heterologous antigens in live cell V. cholerae strains |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| KR100619350B1 (ko) * | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
| US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| US20040258703A1 (en) * | 1997-11-14 | 2004-12-23 | The Government Of The Us, As Represented By The Secretary Of The Army | Skin-active adjuvants for transcutaneous immunization |
| AU3089599A (en) * | 1998-03-18 | 1999-10-11 | Smithkline Beecham Corporation | Production of purified mutant enterotoxin for use as an adjuvant |
| US6033673A (en) * | 1998-03-18 | 2000-03-07 | The Administrators Of Tulane Educational Fund | Double mutant enterotoxin for use as an adjuvant |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| EP1105490A1 (en) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| GB9819484D0 (en) * | 1998-09-07 | 1998-10-28 | Univ Bristol | Therapeutic agents |
| US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| CA2365392C (en) * | 1999-03-03 | 2010-12-14 | The Kitasato Institute | Vaccine preparation containing fatty acid as a constituent |
| US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
| GB9919468D0 (en) | 1999-08-17 | 1999-10-20 | Smithkline Beecham Biolog | Vaccine |
| US7722887B1 (en) * | 1999-09-15 | 2010-05-25 | Mogam Biotechnology Research Institute | Detoxified mutants of escherichia coli heat-labile enterotoxin |
| US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
| ES2462532T3 (es) * | 1999-10-18 | 2014-05-23 | Novartis Vaccines And Diagnostics, Inc. | Composiciones y métodos para estimular una respuesta inmune contra agentes infecciosos |
| AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
| AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
| MY128159A (en) * | 2000-06-30 | 2007-01-31 | Wyeth Corp | Methods and composition for oral vaccination |
| US7364739B2 (en) | 2000-08-25 | 2008-04-29 | National Research Council Of Canada | Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections |
| EP1316314A4 (en) * | 2000-08-31 | 2004-12-29 | Kitasato Inst | PREPARATION OF A VACCINE CONTAINING FATTY ACID AS A COMPOUND |
| ATE398461T1 (de) * | 2001-02-13 | 2008-07-15 | Us Gov Sec Army | Impstoffe zur transkutanen immunisierung gegen reisediarrhö |
| JP2004529906A (ja) | 2001-03-19 | 2004-09-30 | イオマイ コーポレイシヨン | 経皮的免疫賦活 |
| IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
| CN1977971A (zh) | 2001-06-07 | 2007-06-13 | 惠氏控股有限公司 | 作为佐剂的霍乱全毒素的突变体形式 |
| EP1423142A1 (en) * | 2001-08-31 | 2004-06-02 | Chiron SRL. | Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| GB0121998D0 (en) * | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
| NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
| ES2320119T3 (es) * | 2002-08-27 | 2009-05-19 | Dow Agrosciences Llc | Uso de toxina remolabil de escherichia coli como adyvante en aves de corral. |
| WO2004043286A2 (en) * | 2002-11-14 | 2004-05-27 | Pfizer Products Inc. | Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen |
| US20040171565A1 (en) * | 2003-02-14 | 2004-09-02 | David Hone | DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity |
| US20060069052A1 (en) * | 2003-02-14 | 2006-03-30 | David Hone | DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity |
| WO2005019412A2 (en) | 2003-05-20 | 2005-03-03 | New York University | Mucosal immunization to prevent prion infection |
| US8685718B2 (en) * | 2003-05-20 | 2014-04-01 | New York University | Mucosal immunization to prevent prion infection |
| RU2368392C2 (ru) | 2003-09-02 | 2009-09-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Применение аттенуированного ротавирусного штамма серотипа g1 в изготовлении композиции для индукции иммунного ответа на ротавирусную инфекцию |
| US20060002960A1 (en) * | 2003-12-09 | 2006-01-05 | Paul Zoeteweij | GM1 binding deficient exotoxins for use as immunoadjuvants |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN100387719C (zh) * | 2005-05-09 | 2008-05-14 | 中国农业科学院生物技术研究所 | 编码大肠杆菌热敏毒素基因及其表达载体和用途 |
| EP1922416A2 (en) * | 2005-09-09 | 2008-05-21 | Universität Zürich | Antigens for vaccination against and detection of mycoplasma suis |
| WO2007091911A1 (fr) * | 2006-02-09 | 2007-08-16 | Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk | Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures |
| AU2007219615B2 (en) | 2006-03-03 | 2013-11-28 | Promis Neurosciences Inc. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| CN101688194B (zh) | 2007-05-23 | 2013-09-11 | Uab研究基金会 | 去毒的肺炎球菌神经氨酸酶及其用途 |
| JP5576792B2 (ja) * | 2007-07-18 | 2014-08-20 | ディベロップメント センター フォー バイオテクノロジー | 変異型大腸菌易熱性エンテロトキシン |
| DE102007037301A1 (de) * | 2007-08-07 | 2009-02-12 | BSH Bosch und Siemens Hausgeräte GmbH | Hausgeräteanordnung |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| AU2008299536B2 (en) | 2007-09-11 | 2014-06-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium difficile |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| WO2010002867A2 (en) * | 2008-07-01 | 2010-01-07 | The Goerge Washington University | Multivalent antihelminthic vaccine |
| US7927586B2 (en) * | 2008-07-08 | 2011-04-19 | South Dakota State University | Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli |
| EP2376526A4 (en) | 2008-12-24 | 2013-02-27 | Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M | MODIFIED STREPTOCOCCUS PNEUMONIAE PNEUMOLYSIN (PLY) POLYPEPTIDE |
| TW201103980A (en) | 2009-07-08 | 2011-02-01 | Abbott Biologicals Bv | Viral vaccine and use thereof |
| EP2668201A2 (en) | 2011-01-28 | 2013-12-04 | Sanofi Pasteur SA | Immunological compositions comprising hiv gp41 polypeptide derivatives |
| WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP2865390B1 (en) | 2012-06-20 | 2019-08-21 | The University of Tokyo | Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection |
| WO2014044690A1 (en) | 2012-09-18 | 2014-03-27 | Valneva Austria Gmbh | Improved vaccines |
| WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
| WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
| US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
| WO2017079835A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| KR20180085736A (ko) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
| CN108350051A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
| GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CN110075290A (zh) * | 2018-01-25 | 2019-08-02 | 吴夙钦 | 流感黏膜疫苗组合物及其制备方法与应用 |
| IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
| IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| IT1253009B (it) * | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| US6033673A (en) * | 1998-03-18 | 2000-03-07 | The Administrators Of Tulane Educational Fund | Double mutant enterotoxin for use as an adjuvant |
-
1994
- 1994-08-26 US US08/296,848 patent/US6019982A/en not_active Expired - Lifetime
-
1995
- 1995-07-18 CZ CZ0056297A patent/CZ298131B6/cs not_active IP Right Cessation
- 1995-07-18 AU AU32337/95A patent/AU709779B2/en not_active Ceased
- 1995-07-18 PL PL95318930A patent/PL182667B1/pl not_active IP Right Cessation
- 1995-07-18 EP EP95928662A patent/EP0777490B1/en not_active Expired - Lifetime
- 1995-07-18 WO PCT/US1995/009005 patent/WO1996006627A1/en active IP Right Grant
- 1995-07-18 DK DK95928662T patent/DK0777490T3/da active
- 1995-07-18 AT AT95928662T patent/ATE326231T1/de active
- 1995-07-18 ES ES95928662T patent/ES2265148T3/es not_active Expired - Lifetime
- 1995-07-18 PT PT95928662T patent/PT777490E/pt unknown
- 1995-07-18 KR KR1019970701224A patent/KR100399258B1/ko not_active IP Right Cessation
- 1995-07-18 DE DE69534992T patent/DE69534992T2/de not_active Expired - Lifetime
- 1995-07-18 CA CA2198586A patent/CA2198586C/en not_active Expired - Fee Related
- 1995-07-18 CN CNB951958380A patent/CN1182868C/zh not_active Expired - Fee Related
- 1995-07-18 JP JP50873596A patent/JP3860208B2/ja not_active Expired - Fee Related
- 1995-07-18 NZ NZ291262A patent/NZ291262A/xx not_active IP Right Cessation
- 1995-07-18 RU RU97104479/14A patent/RU2160606C2/ru not_active IP Right Cessation
- 1995-07-18 HU HU9801472A patent/HU222985B1/hu not_active IP Right Cessation
- 1995-07-18 BR BR9508633A patent/BR9508633A/pt not_active Application Discontinuation
- 1995-08-01 ZA ZA956412A patent/ZA956412B/xx unknown
-
1997
- 1997-02-26 FI FI970799A patent/FI120137B/fi not_active IP Right Cessation
- 1997-03-04 NO NO19970993A patent/NO317942B1/no not_active IP Right Cessation
-
1999
- 1999-08-02 US US09/365,530 patent/US6440423B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970705403A (ko) | 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant) | |
| RU97104479A (ru) | Мутант энтеротоксина, эффективный в качестве нетоксичного орального стимулятора | |
| CA2179771C (en) | Non-toxic mucosal adjuvant | |
| Mäkelä | Vaccines, coming of age after 200 years | |
| CA2332963C (en) | Combination meningitidis b/c vaccines | |
| Del Giudice et al. | What are the limits of adjuvanticity? | |
| WO2000050006A3 (en) | Microemulsions with adsorbed macromoelecules and microparticles | |
| BR0210216A (pt) | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante | |
| BR0210225A (pt) | Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante | |
| RU2000116260A (ru) | Вакцины с адъювантом ltb | |
| US6436407B1 (en) | Mutant enterotoxin effective as a non-toxic adjuvant | |
| EP0837692B1 (en) | Clostridium difficile toxins and toxoids as mucosal adjuvants | |
| KR920004422A (ko) | Hiv의 주요 중화 결정인자 | |
| CN101559223A (zh) | 流脑白百破联合疫苗 | |
| EP1741443A2 (en) | Combination meningitidis B/C vaccines | |
| CA2348658A1 (en) | Vaccine preparations containing attenuated toxin | |
| JP5148577B2 (ja) | 非毒性の粘膜アジュバント | |
| McGhee et al. | Oral immunization: a summary | |
| JP2004262847A (ja) | ワクチン製剤 | |
| RU2000130221A (ru) | Антигены neisseria meningitidis и композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20110830 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20120827 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |